Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study

David Jayne, Daniel Blockmans, Raashid Luqmani, Sergey Moiseev, Beulah Ji, Yulia Green, Leanne Hall, David Roth, Robert B Henderson, Peter A Merkel, BREVAS Study Collaborators, Jose Alfaro Lozano, Heidemarie Becker, Armando Calvo Quiroz, Simon Carette, Sandra Carrillo-Vazquez, María C Cid, David D'Cruz, Atul Deodhar, Oliver Flossman, Giacomo Garibotto, Loreto Gesualdo, Stephen Hall, Thomas Hauser, Bernhard Hellmich, Dana Kidder, Martin Kimmel, Mark Little, Maria Majdan, Kathleen Maksimowicz-McKinnon, Galina Marder, Galina Matsievskaia, Ariel Salinas Meneses, Eamonn Molloy, Ruediger Mueller, Clark Neuwelt, Jorge L Ravelo, Ulrich Specks, Vladimir Tesar, Michael Walsh, David Jayne, Daniel Blockmans, Raashid Luqmani, Sergey Moiseev, Beulah Ji, Yulia Green, Leanne Hall, David Roth, Robert B Henderson, Peter A Merkel, BREVAS Study Collaborators, Jose Alfaro Lozano, Heidemarie Becker, Armando Calvo Quiroz, Simon Carette, Sandra Carrillo-Vazquez, María C Cid, David D'Cruz, Atul Deodhar, Oliver Flossman, Giacomo Garibotto, Loreto Gesualdo, Stephen Hall, Thomas Hauser, Bernhard Hellmich, Dana Kidder, Martin Kimmel, Mark Little, Maria Majdan, Kathleen Maksimowicz-McKinnon, Galina Marder, Galina Matsievskaia, Ariel Salinas Meneses, Eamonn Molloy, Ruediger Mueller, Clark Neuwelt, Jorge L Ravelo, Ulrich Specks, Vladimir Tesar, Michael Walsh

Abstract

Objective: To evaluate the safety and efficacy of belimumab as adjunctive therapy to maintain remission in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).

Methods: In this multicenter, double-blind, placebo-controlled study, patients with AAV (ages ≥18 years) were randomized 1:1 to receive azathioprine (2 mg/kg/day), low-dose oral glucocorticoids (≤10 mg/day), and either intravenous belimumab (10 mg/kg) or placebo, following remission induction with rituximab or cyclophosphamide along with glucocorticoids. The primary end point was time to first protocol-specified event (PSE), with first PSE defined as a Birmingham Vasculitis Activity Score (BVAS) of ≥6, presence of ≥1 major BVAS item, or receipt of prohibited medications for any reason, resulting in treatment failure (adjusted for ANCA type [proteinase 3 (PR3) or myeloperoxidase (MPO)], disease stage at induction, and induction regimen). Vasculitis relapse was defined as the PSE of either a BVAS activity score of ≥6 or receipt of prohibited medications for vasculitis. Changes in treatment practice led to truncation of the study population from ~300 patients to ~100 patients.

Results: The intent-to-treat population totaled 105 patients with AAV, of whom 52 (40 with PR3-ANCAs, 12 with MPO-ANCAs) received placebo and 53 (41 with PR3-ANCAs, 12 with MPO-ANCAs) received belimumab; 27 of the patients were in rituximab-induced disease remission, while 78 were in cyclophosphamide-induced disease remission at baseline. Compared with placebo, treatment with belimumab did not reduce the risk of a PSE (adjusted hazard ratio [HR] 1.07, 95% confidence interval [95% CI] 0.44-2.59; P = 0.884) or vasculitis relapse (adjusted HR 0.88, 95% CI 0.29-2.65; P = 0.821). The overall rate of PSEs was low (11 [21.2%] of 52 patients receiving placebo, 10 [18.9%] of 53 patients receiving belimumab). Vasculitis relapse in the placebo group (n = 8) occurred independent of the induction regimen, disease stage, or ANCA type. All vasculitis relapses in the belimumab group (n = 6) occurred in patients who had PR3-ANCA-associated vasculitis with cyclophosphamide-induced disease remission. Adverse events occurred in 49 (92.5%) of 53 patients receiving belimumab and 43 (82.7%) of 52 patients receiving placebo, with no new safety concerns.

Conclusion: Belimumab plus azathioprine and glucocorticoids for the maintenance of remission in AAV did not reduce the risk of relapse.

Trial registration: ClinicalTrials.gov NCT01663623.

© 2019 The Authors. Arthritis & Rheumatology published by Wiley Periodicals, Inc. on behalf of American College of Rheumatology.

Figures

Figure 1
Figure 1
Study design. BVAS = Birmingham Vasculitis Activity Score; IV = intravenous; R = randomization; PSE = protocol‐specified event.
Figure 2
Figure 2
Distribution of patients in the intent‐to‐treat (ITT) population. a = not all patients who withdrew due to lack of efficacy met the protocol‐specified event (PSE) criteria (n = 1 in the belimumab group and n = 2 in the placebo group did not meet the criteria), and in some cases in which patients experienced a PSE, the reason for discontinuation was reported as an adverse event rather than lack of efficacy. b = includes patients withdrawn from the study; patients who discontinued treatment with placebo or belimumab continued in the study until relapse, study withdrawal, or study completion. c = reasons for withdrawal included patient decision (n = 2), study termination (Italy) (n = 1), and protocol deviation (n = 1). d = reasons for withdrawal included patient decision (n = 3), study termination (Italy) (n = 1), protocol deviation (n = 3), and investigator decision (n = 2).
Figure 3
Figure 3
A, Kaplan‐Meier plot of time to first vasculitis relapse in each treatment group. Vasculitis relapse was defined as a Birmingham Vasculitis Activity Score (BVAS) of ≥6, presence of a major BVAS item, or receipt of a prohibited medication for vasculitis. B, Occurrence of vasculitis relapse, as defined in A, in patients according to disease status at screening (initial versus relapsing disease). RTX = rituximab; CYC = cyclophosphamide; PR3 = proteinase 3; MPO = myeloperoxidase.

References

    1. Cartin‐Ceba R, Peikert T, Specks U. Pathogenesis of ANCA‐associated vasculitis. Curr Rheumatol Rep 2012;14:481–93.
    1. Jennette JC, Falk RJ. Small‐vessel vasculitis. N Engl J Med 1997;337:1512–23.
    1. Yates M, Watts R, Bajema I, Cid M, Crestani B, Hauser T, et al. EULAR/ERA‐EDTA recommendations for the management of ANCA‐associated vasculitis. Ann Rheum Dis 2016;75:1583–94.
    1. Guillevin L, Pagnoux C, Karras A, Khouatra C, Aumaître O, Cohen P, et al. Rituximab versus azathioprine for maintenance in ANCA‐associated vasculitis. N Engl J Med 2014;371:1771–80.
    1. Turner‐Stokes T, Sandhu E, Pepper RJ, Stolagiewicz NE, Ashley C, Dinneen D, et al. Induction treatment of ANCA‐associated vasculitis with a single dose of rituximab. Rheumatology (Oxford) 2014;53:1395–403.
    1. Cambridge G, Stohl W, Leandro MJ, Migone TS, Hilbert DM, Edwards JC. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum 2006;54:723–32.
    1. Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al. Rituximab versus cyclophosphamide for ANCA‐associated vasculitis. N Engl J Med 2010;363:221–32.
    1. Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, et al. Rituximab versus cyclophosphamide in ANCA‐associated renal vasculitis. N Engl J Med 2010;363:211–20.
    1. Bader L, Koldingsnes W, Nossent J. B‐lymphocyte activating factor levels are increased in patients with Wegener's granulomatosis and inversely correlated with ANCA titer. Clin Rheumatol 2010;29:1031–5.
    1. Holden N, Williams J, Morgan M, Challa A, Gordon J, Pepper R, et al. ANCA‐stimulated neutrophils release BLyS and promote B cell survival: a clinically relevant cellular process. Ann Rheum Dis 2011;70:2229–33.
    1. Schneeweis C, Rafalowicz M, Feist E, Buttgereit F, Rudolph P, Burmester G, et al. Increased levels of BLyS and sVCAM‐1 in anti‐neutrophil cytoplasmatic antibody (ANCA)‐associated vasculitides (AAV). Clin Exp Rheumatol 2010;28:S62–6.
    1. Scapini P, Nardelli B, Nadali G, Calzetti F, Pizzolo G, Montecucco C, et al. G‐CSF‐stimulated neutrophils are a prominent source of functional BLyS. J Exp Med 2003;197:297–302.
    1. Schneider P, MacKay F, Steiner V, Hofmann K, Bodmer JL, Holler N, et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 1999;189:1747–56.
    1. Krumbholz M, Specks U, Wick M, Kalled SL, Jenne D, Meinl E. BAFF is elevated in serum of patients with Wegener's granulomatosis. J Autoimmun 2005;25:298–302.
    1. Nagai M, Hirayama K, Ebihara I, Shimohata H, Kobayashi M, Koyama A. Serum levels of BAFF and APRIL in myeloperoxidase anti‐neutrophil cytoplasmic autoantibody‐associated renal vasculitis: association with disease activity. Nephron Clin Pract 2011;118:c339–45.
    1. Xin G, Su Y, Li KS, Chen M, Zhao MH, Xu LX. Serum B‐cell activating factor in myecloperoxiase‐antineutrophil cytoplasmic antibodies‐associated vasculitis. Am J Med Sci 2014;348:25–9.
    1. Carter LM, Isenberg DA, Ehrenstein MR. Elevated serum BAFF levels are associated with rising anti–double‐stranded DNA antibody levels and disease flare following B cell depletion therapy in systemic lupus erythematosus. Arthritis Rheum 2013;65:2672–9.
    1. Lavie F, Miceli‐Richard C, Ittah M, Sellam J, Gottenberg JE, Mariette X. Increase of B cell‐activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production. Ann Rheum Dis 2007;66:700–3.
    1. Lesley R, Xu Y, Kalled SL, Hess DM, Schwab SR, Shu HB, et al. Reduced competitiveness of autoantigen‐engaged B cells due to increased dependence on BAFF. Immunity 2004;20:441–53.
    1. Thien M, Phan TG, Gardam S, Amesbury M, Basten A, Mackay F, et al. Excess BAFF rescues self‐reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 2004;20:785–98.
    1. Vallerskog T, Heimburger M, Gunnarsson I, Zhou W, Wahren‐Herlenius M, Trollmo C, et al. Differential effects on BAFF and APRIL levels in rituximab‐treated patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther 2006;8:R167.
    1. Baker KP, Edwards BM, Main SH, Choi GH, Wager RE, Halpern WG, et al. Generation and characterization of LymphoStat‐B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum 2003;48:3253–65.
    1. Benlysta (belimumab) prescribing information. Rockville (MD): GlaxoSmithKline; 2018. URL: .
    1. World Medical Association . World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 2013;310:2191–4.
    1. Jennette JC. Overview of the 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Clin Exp Nephrol 2013;17:603–6.
    1. Mukhtyar C, Lee R, Brown D, Carruthers D, Dasgupta B, Dubey S, et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis 2009;68:1827–32.
    1. Suppiah R, Mukhtyar C, Flossmann O, Alberici F, Baslund B, Batra R, et al. A cross‐sectional study of the Birmingham Vasculitis Activity Score version 3 in systemic vasculitis. Rheumatology (Oxford) 2011;50:899–905.
    1. Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, et al. The Columbia‐Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry 2011;168:1266–77.
    1. Jones RB, Furuta S, Tervaert JW, Hauser T, Luqmani R, Morgan MD, et al. Rituximab versus cyclophosphamide in ANCA‐associated renal vasculitis: 2‐year results of a randomised trial. Ann Rheum Dis 2015;74:1178–82.
    1. Ansell SM, Novak AJ, Ziesmer S, Price‐Troska T, LaPlant B, Dillon SR, et al. Serum BLyS levels increase after rituximab as initial therapy in patients with follicular grade 1 non‐Hodgkin lymphoma. Am J Hematol 2009;84:71–3.
    1. Karras A, Pagnoux C, Haubitz M, Groot K, Puechal X, Tervaert JW, et al. Randomised controlled trial of prolonged treatment in the remission phase of ANCA‐associated vasculitis. Ann Rheum Dis 2017;76:1662–8.
    1. Gong Q, Ou Q, Ye S, Lee WP, Cornelius J, Diehl L, et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol 2005;174:817–26.
    1. Kraaij T, Huizinga TW, Rabelink TJ, Teng YO. Belimumab after rituximab as maintenance therapy in lupus nephritis. Rheumatology (Oxford) 2014;53:2122–4.
    1. Lin W, Seshasayee D, Lee WP, Caplazi P, McVay S, Suto E, et al. Dual B cell immunotherapy is superior to individual anti‐CD20 depletion or BAFF blockade in murine models of spontaneous or accelerated lupus. Arthritis Rheumatol 2015;67:215–24.
    1. Simonetta F, Allali D, Roux‐Lombard P, Chizzolini C. Successful treatment of refractory lupus nephritis by the sequential use of rituximab and belimumab [letter]. Joint Bone Spine 2017;84:235–6.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner